INS and fatty liver disease: For instance, adipocyte-selective overexpression of PFKFB3/iPFK2, which activates 6-phosphofructo-1-kinase (6PFK1) to enhance glycolysis, decreased HFD-induced liver proinflammatory response and improved insulin signaling; although leading to increased hepatic steatosis (119–121).